Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.54 |
| ▸ | CDC25B | P30305 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442586 | 0.90 | LMNA (0.50) | CNR2CDC25BLMNACNR1FABP4 | |
| SCHEMBL7905505 | 0.86 | CNR2 (0.54) | CNR2LMNACNR1GLAL3MBTL1 | |
| SCHEMBL27624634 | 0.85 | CNR2 (0.68) | CNR2CDC25BCNR1FABP4CYP2C9 | |
| SCHEMBL11171232 | 0.85 | CNR2 (0.53) | CNR2LMNACNR1GLAL3MBTL1 | |
| SCHEMBL5232608 | 0.85 | CNR2 (0.53) | CNR2LMNACNR1GLAL3MBTL1 | |
| SCHEMBL249271 | 0.84 | CNR2 (0.69) | CNR2LMNACNR1FABP4CYP2C9 | |
| SCHEMBL20520346 | 0.83 | THRA (0.53) | CNR2CNR1GLAL3MBTL1CYP2C9 | |
| SCHEMBL6564798 | 0.83 | KDM4E (0.60) | CNR2CDC25BCNR1GLAL3MBTL1 | |
| SCHEMBL27823508 | 0.81 | FOLH1 (0.57) | CNR2CDC25BCNR1FABP4L3MBTL1 | |
| SCHEMBL29378631 | 0.81 | ALDH1A1 (0.54) | CNR2LMNAGLAL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117416983-A | Naphthoxyhc acid and/or its derivative acid radical intercalation hydrotalcite-like compound and its preparation method | 中国科学院青海盐湖研究所 | 2024-01-19 | — | — | CN | claimed |
| CN-117416983-A | Naphthoxyhc acid and/or its derivative acid radical intercalation hydrotalcite-like compound and its preparation method | 中国科学院青海盐湖研究所 | 2024-01-19 | — | — | CN | disclosed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | CNR2 1/4885CDC25B 2359/4885LMNA 3275/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CNR2 11/4885CDC25B 3025/4885LMNA 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.